- In January 2024, RTI Surgical completed its acquisition of Cook Biotech, a move to strengthen its position in the surgical and regenerative medicine markets. This acquisition allows RTI to expand its portfolio of biologic and synthetic products, enhancing its ability to provide innovative solutions for surgical procedures. Integrating Cook Biotech's expertise in hernia repair and wound management is expected to drive growth and improve patient outcomes
- In April 2024, the company planned to launch a new smaller version of the T-Line Mesh, named the T-Line Mini, which was designed for umbilical hernias and small defects. Biosynthetic and coated composite versions of the T-Line Hernia Mesh were also under development
- In March 2024, TELA Bio, Inc., a commercial-stage medical technology company specializing in advanced soft-tissue reconstruction solutions, announced the U.S. release of LIQUIFIX FIX8™ Laparoscopic and LIQUIFIX Precision™ Open Hernia Mesh Fixation Devices. LIQUIFIX FIX8 is designed for minimally invasive repair of femoral and inguinal hernias, while LIQUIFIX Precision is intended for open repair of femoral and inguinal hernias
- In January 2022, Cook Biotech Inc. announced a partnership with the European Hernia Society (EHS) to advance hernia repair technologies. This collaboration aims to promote research, education, and clinical practice related to hernia management. By joining forces, Cook Biotech and EHS intend to enhance the understanding of hernia repair procedures and improve patient outcomes through innovative solutions. The partnership underscores a commitment to developing effective treatment options and fostering collaboration within the medical community.
- December 2022 – W. L. Gore & Associates, Inc. partnered with AGC Biologics for protein A-based purification technology, intending to reduce the manufacturing footprint and the clinical manufacturing cost of its products.
